“…The new membrane flow OSOM assay from Genzyme is thought to have excellent sensitivity and specificity, with limited skill required to process and interpret the test, but the test is available for use only on female specimens and may be cost-prohibitive (11). In spite of this, levels of infection have typically been high, with reported overall prevalences ranging from 3% to 58% and an unweighted average across studies of 19.6% (4,6,7,10,15,18,20,24,33,37,60,62,64,69,70,77,90,92,95,99,108). Table 1 lists published reports on the occurrence of T. vaginalis infection among women conducted among U.S. populations from 1964 through 2007.…”